Fertipraxis Centro de Reproducao Humana. Rio de Janeiro, RJ, Brazil.
Instituto Antioqueño de Reproducción. Medellin, Colombia.
JBRA Assist Reprod. 2023 Sep 12;27(3):539-546. doi: 10.5935/1518-0557.20230035.
To follow the impact of the SARS-CoV-2 pandemic on the practice of assisted reproductive technology in centers reporting to the Latin American Registry during 2020.
An internally validated online survey designed on the Survey Monkey platform with a maximum of 20 closed questions was sent via e-mail or WhatsApp to the clinical director of each center reporting to the Latin American Registry of Assisted Reproduction between July and December 2020.
The number of centers responding to the survey varied during the six months. The relative contribution of Brazil to all responses was 41.4% to 45%, followed by México (16.2% to 23.8%), Argentina (8.1% to 12.6%), Colombia (7.1% to 8.2%), Chile (3.6% to 6.1%) and Peru (4.0% to 4.9%). Most centers reported stopping activities before July 2020 (81%). COVID-19 related symptoms were a criterion on their own to postpone ovarian stimulation (80.1% to 87.7% of centers). Although in July only 76 of 166 centers (45.8%) performed embryo transfers, by October 104 of 109 centers (95.4%) performed them. In survey 6 (December), 78 of 79 centers (98.7%) that had initially closed had already reopened, although 62.3% (61 of 98 centers) still performed 80% or less of their usual number of ART cycles.
Most centers modified their clinical practice and applied specific protocols to screen their staff and patients. Suspicion of COVID-19 delayed treatments. Despite a peak of the pandemic, by December most centers were performing all ART treatments, although the number of cycles remained low compared to pre-pandemic numbers.
了解 2020 年拉丁美洲辅助生殖技术注册中心报告的新冠疫情对辅助生殖技术实践的影响。
采用 Survey Monkey 平台设计内部验证的在线调查,最多包含 20 个封闭问题,于 2020 年 7 月至 12 月期间通过电子邮件或 WhatsApp 发送给拉丁美洲辅助生殖技术注册中心的临床主任。
六个月期间,对调查做出回应的中心数量有所不同。巴西对所有回复的相对贡献为 41.4%至 45%,其次是墨西哥(16.2%至 23.8%)、阿根廷(8.1%至 12.6%)、哥伦比亚(7.1%至 8.2%)、智利(3.6%至 6.1%)和秘鲁(4.0%至 4.9%)。大多数中心报告在 2020 年 7 月之前停止了活动(81%)。与 COVID-19 相关的症状是单独推迟卵巢刺激的标准(80.1%至 87.7%的中心)。尽管 2020 年 7 月仅有 166 个中心中的 76 个(45.8%)进行了胚胎移植,但到 10 月,109 个中心中的 104 个(95.4%)进行了移植。在第六次调查(12 月)中,最初关闭的 79 个中心中的 78 个(98.7%)已经重新开放,尽管 62.3%(98 个中心中的 61 个)仍执行其通常的 ART 周期数量的 80%或更少。
大多数中心修改了其临床实践,并应用了特定的方案来筛查其员工和患者。对 COVID-19 的怀疑延迟了治疗。尽管疫情达到高峰,但到 12 月,大多数中心都在进行所有的 ART 治疗,尽管与大流行前相比,周期数量仍然较低。